Funded Grants

The V Foundation’s grant making model ensures the most promising cancer research projects at state-of-the-art facilities around the country are funded. Cancer research grants are awarded to innovative researchers with the most cutting-edge ideas on how to improve cancer diagnosis methods, prevent cancer recurrences or defeat cancer. 100% of direct donations are used to fund projects we identify as the most likely to help those diagnosed with cancer.

2026
Paula Pohlmann, MD, MSc, PhD
HER2 Vaccine Trial in Early Stage HER2 Positive Breast Cancer - INTERCEPT-HER2...
Read More
2026
Michael Haffner, MD, PhD
AKTing on DNA hypomethylation
Read More
2026
Grant Challen, PhD
The Genomic Basis of Telomerase Inhibitor Sensitivity in Myelodysplastic Syndrome Patients
Read More
2026
Denis Guttridge, Phd
The role of IL-1 crosstalk in pancreatic cancer-induced cachexia
Read More
2026
Benjamin Izar, MD, PhD
Restoring anti-tumor immunity in chromosomally unstable solid cancers
Read More
2026
Trudy Oliver, PhD
PIK3CG as a novel target for tuft-like lung cancer
Read More
2026
Andrew Lane, MD, PhD
Targeting unique residual disease biology to improve survival for patients with leukemia
Read More
2026
Natalie Silver, MD, MS, FACS
Precision Immunotherapy to Reprogram the Tumor Immune Microenvironment in Anaplastic Thyroid Cancer
Read More
2026
Christian Hinrichs, MD
Off-the-shelf HPV16 TCR engagers for adult HPV-driven cancers
Read More
2026
Michelle Ozbun, PhD
Topical Trametinib for HPV Precancer Interception: Optimizing Dose, Formulation, Schedule, PK, and...
Read More
2026
Jeffrey Smith, MD, PhD
Prostate Cancer Clinical Significance as Genetic Functions of Grade and Stage
Read More
2026
Elsa Flores, PhD
Targeting “undruggable” pathways in tumor progression and therapy resistance
Read More
2026
Amit Verma, MD
Targeting Inflammation in Myeloid Malignancies
Read More
2026
Justin Milner, PhD
Synthetic Reprogramming of CAR-T Cells for the Treatment of Pancreatic Cancer
Read More
2026
Frank B. Furnari, PhD
Developing Combination Therapies to Target GBM Persister Cells
Read More
2026
Kira Gritsman, MD, PhD
PI3 kinase delta inhibition in combination with venetoclax and hypomethylating agents for...
Read More